These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 23626690

  • 1. A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.
    Demurtas OC, Massa S, Ferrante P, Venuti A, Franconi R, Giuliano G.
    PLoS One; 2013; 8(4):e61473. PubMed ID: 23626690
    [Abstract] [Full Text] [Related]

  • 2. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S, Ferrall L, Gaillard S, Wang C, Chi WY, Huang CH, Roden RBS, Wu TC, Chang YN, Hung CF.
    mBio; 2021 Jan 19; 12(1):. PubMed ID: 33468698
    [Abstract] [Full Text] [Related]

  • 3. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
    Cheng WF, Chang MC, Sun WZ, Jen YW, Liao CW, Chen YY, Chen CA.
    PLoS One; 2013 Jan 19; 8(9):e71216. PubMed ID: 24058440
    [Abstract] [Full Text] [Related]

  • 4. A Genetically Modified attenuated Listeria Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner.
    Jia YY, Tan WJ, Duan FF, Pan ZM, Chen X, Yin YL, Jiao XA.
    Front Cell Infect Microbiol; 2017 Jan 19; 7():279. PubMed ID: 28706878
    [Abstract] [Full Text] [Related]

  • 5. Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
    Talebi S, Bolhassani A, Azad TM, Arashkia A, Modaresi MH.
    Protein Pept Lett; 2017 Jan 19; 24(3):190-196. PubMed ID: 28000571
    [Abstract] [Full Text] [Related]

  • 6. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice.
    Granadillo M, Vallespi MG, Batte A, Mendoza O, Soria Y, Lugo VM, Torrens I.
    Vaccine; 2011 Jan 29; 29(5):920-30. PubMed ID: 21145912
    [Abstract] [Full Text] [Related]

  • 7. Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model.
    Salehi M, Taheri T, Mohit E, Zahedifard F, Seyed N, Taslimi Y, Sattari M, Bolhassani A, Rafati S.
    Immunotherapy; 2012 Nov 29; 4(11):1107-20. PubMed ID: 23194361
    [Abstract] [Full Text] [Related]

  • 8. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines.
    Shahbazi S, Bolhassani A.
    Int Immunopharmacol; 2018 Sep 29; 62():170-180. PubMed ID: 30015237
    [Abstract] [Full Text] [Related]

  • 9. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice.
    Bahrami AA, Ghaemi A, Tabarraei A, Sajadian A, Gorji A, Soleimanjahi H.
    J Virol Methods; 2014 Sep 29; 206():12-8. PubMed ID: 24880067
    [Abstract] [Full Text] [Related]

  • 10. Immunological responses and anti-tumor effects of HPV16/18 L1-L2-E7 multiepitope fusion construct along with curcumin and nanocurcumin in C57BL/6 mouse model.
    Kayyal M, Bolhassani A, Noormohammadi Z, Sadeghizadeh M.
    Life Sci; 2021 Nov 15; 285():119945. PubMed ID: 34516991
    [Abstract] [Full Text] [Related]

  • 11. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
    Sharma RK, Srivastava AK, Yolcu ES, MacLeod KJ, Schabowsky RH, Madireddi S, Shirwan H.
    Vaccine; 2010 Aug 16; 28(36):5794-802. PubMed ID: 20603135
    [Abstract] [Full Text] [Related]

  • 12. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S, Mohebbi A, Vakilzadeh G, Biglari P, Razeghi Jahromi S, Mohebi SR, Shirian S, Gorji A, Ghaemi A.
    Arch Virol; 2018 Mar 16; 163(3):587-597. PubMed ID: 29149434
    [Abstract] [Full Text] [Related]

  • 13. HPV16 mutant E6/E7 construct is protective in mouse model.
    Goodarzi MM, Mosayebi G, Ganji A, Raoufi E, Sadelaji S, Babaei S, Abtahi H.
    BMC Biotechnol; 2024 Sep 30; 24(1):71. PubMed ID: 39350162
    [Abstract] [Full Text] [Related]

  • 14. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells.
    Komatsu A, Igimi S, Kawana K.
    Vaccine; 2018 Jun 07; 36(24):3423-3426. PubMed ID: 29735324
    [Abstract] [Full Text] [Related]

  • 15. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
    Jia Y, Yin Y, Duan F, Fu H, Hu M, Gao Y, Pan Z, Jiao X.
    Int J Mol Med; 2012 Dec 07; 30(6):1335-42. PubMed ID: 23027427
    [Abstract] [Full Text] [Related]

  • 16. Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana.
    Yanez RJR, Lamprecht R, Granadillo M, Weber B, Torrens I, Rybicki EP, Hitzeroth II.
    PLoS One; 2017 Dec 07; 12(8):e0183177. PubMed ID: 28800364
    [Abstract] [Full Text] [Related]

  • 17. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
    Tang J, Yin R, Tian Y, Huang Z, Shi J, Fu X, Wang L, Wu Y, Hao F, Ni B.
    Vaccine; 2012 Feb 01; 30(6):1071-82. PubMed ID: 22178528
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses.
    Kayyal M, Bolhassani A, Noormohammadi Z, Sadeghizadeh M.
    Mol Biotechnol; 2021 Dec 01; 63(12):1192-1222. PubMed ID: 34308516
    [Abstract] [Full Text] [Related]

  • 20. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S, Zhang W, Hu X, Wang W, Deng D, Wang H, Wang C, Zhou J, Wang S, Zhang H, Ma D.
    Mol Immunol; 2015 Apr 01; 64(2):295-305. PubMed ID: 25575128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.